Labcorp Holdings Inc. (LH)
| Market Cap | 26.75B +13.8% |
| Revenue (ttm) | 14.35B +6.4% |
| Net Income | 1.00B +31.3% |
| EPS | 12.08 +33.2% |
| Shares Out | 81.10M |
| PE Ratio | 27.32 |
| Forward PE | 17.43 |
| Dividend | $2.88 (0.87%) |
| Ex-Dividend Date | Nov 24, 2026 |
| Volume | 535,741 |
| Open | 329.77 |
| Previous Close | 328.95 |
| Day's Range | 327.07 - 331.76 |
| 52-Week Range | 244.52 - 341.80 |
| Beta | 0.85 |
| Analysts | Buy |
| Price Target | 345.13 (+4.62%) |
| Earnings Date | Oct 28, 2026 |
About LH
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseas... [Read more]
Financial Performance
In 2025, Labcorp Holdings's revenue was $13.95 billion, an increase of 7.25% compared to the previous year's $13.01 billion. Earnings were $876.50 million, an increase of 17.49%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for LH stock is "Buy." The 12-month stock price target is $345.13, which is an increase of 4.62% from the latest price.
News
Waters, Labcorp partner to expand access to cervical cancer screening
Labcorp (LH) and Waters (WAT) announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp’s nationwide laboratory network beginning in late 2026. Cervical cance...
Waters, Labcorp partner to expand access to cervical screening
Labcorp (LH) and Waters (WAT) announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp’s nationwide laboratory network beginning in late 2026. Cervical cance...
Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic, pati...
Labcorp, Charles River and FDA to collaborate to evaluate drug abuse potential
Labcorp (LH) announced a collaboration with the FDA and Charles River Laboratories (CRL) to advance the science used to evaluate a medicine’s abuse potential, or the likelihood that it could…
Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential
Research collaboration aims to strengthen the science used to assess whether new medicines could be abused, supporting safer drug development and more informed regulatory decisions BURLINGTON, N.C., O...
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C., Oct. 21, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has d...
TD says Myriad Genetics prenatal divestiture proceeds ahead of expectations
After Myriad Genetics (MYGN) announced a deal to sell its Prenatal Health testing business to Labcorp (LH) for $210M in cash plus closing inventory, TD Cowen analyst Kyle Boucher said…
Myriad Genetics to sell Prenatal Health testing business to Labcorp
Myriad Genetics (MYGN) announced a definitive agreement for Myriad to sell its Prenatal Health testing business, which includes the Prequel, Foresight, SneakPeek, and FirstGene tests, to Labcorp (LH) ...
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
SALT LAKE CITY and BURLINGTON, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a ...
Three stocks poised to beat estimates this earnings season
Third-quarter earnings season has opened unevenly. JPMorgan, Wells Fargo and Citigroup posted missed results this week, while UnitedHealth topped forecasts for both revenue and profit.
Labcorp to acquire laboratory testing assets of Opko Health subsidiary
Labcorp (LH) and OPKO Health (OPK) have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. Through this transaction,…
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla.
Labcorp and Arianna Huffington's Thrive Global Collaborate to Launch Thrive 5 Health Test
First lab test offered in collaboration with Thrive Global Combines Labcorp's scientific expertise with Thrive Global's behavior change approach to help consumers turn health insights into healthier d...
Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026
BURLINGTON, N.C., Sept. 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc.
Labcorp price target raised to $365 from $350 at Truist
Truist analyst David MacDonald raised the firm’s price target on Labcorp (LH) to $365 from $350 and keeps a Buy rating on the shares as part of a broader research…
Labcorp Holdings Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Long-term guidance through 2026 was reaffirmed, with strong revenue and EPS growth targets, margin expansion, and robust free cash flow. Specialty testing, technology investments, and acquisitions are key growth drivers, while regulatory headwinds like PAMA are actively managed. Oncology, neurology, and consumer health initiatives are highlighted as major opportunities.
Labcorp price target raised to $380 from $361 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on Labcorp (LH) to $380 from $361 and keeps a Buy rating on the shares.
Labcorp price target raised to $330 from $320 at Barclays
Barclays raised the firm’s price target on Labcorp (LH) to $330 from $320 and keeps an Equal Weight rating on the shares following the investor day.
Labcorp Holdings Transcript: Investor Day 2026
The event outlined a strategy centered on specialty testing, technology-driven innovation, and global scale to drive 5%-8% revenue CAGR through 2029, with strong margin and EPS growth. Specialty areas like oncology and neurology are key growth drivers, supported by AI, digital platforms, and disciplined capital deployment.
Labcorp Holdings Slides: FY 2026
Labcorp Holdings has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 10, 2026.
Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
Reaffirms full-year 2026 guidance Provides long-term outlook through 2029, with compound annual revenue growth of 5% to 8% and compound annual adjusted earnings per share (EPS) growth of 8.5% to 11.5%...
Great Point Partners III Sells MLM Medical Labs to Labcorp
GREENWICH, Conn. and MÖNCHENGLADBACH, Germany--(BUSINESS WIRE)--Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, is pleased to a...
Moonwalk Biosciences Announces $70 Million Series B: NYSE Content Update
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept.
Labcorp Acquires MLM Medical Labs, Expanding Global Central Laboratory and Biomarker Capabilities for Clinical Trials
Acquisition establishes Labcorp as the only central laboratory provider with a wholly owned laboratory network across four continents BURLINGTON, N.C., Sept. 8, 2026 /PRNewswire/ -- Labcorp (NYSE: LH)...
Labcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial Complexity
Enhanced digital experience designed to improve visibility, simplify workflows and support faster decision-making BURLINGTON, N.C., Aug. 31, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of...